NRX Pharmaceuticals (NRXP) Change in Accured Expenses (2017 - 2026)

NRX Pharmaceuticals (NRXP) has 10 years of Change in Accured Expenses data on file, last reported at -$68000.0 in Q1 2026.

• On a quarterly basis, Change in Accured Expenses rose 79.82% year-over-year to -$68000.0 in Q1 2026; TTM through Mar 2026 was $770000.0, a 92.08% decrease from a year earlier, with the FY2025 full-year figure at $501000.0, down 94.99% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$68000.0, down from $913000.0 in the prior quarter.
• Over the last five years, Change in Accured Expenses for NRXP reached as high as $10.1 million in Q4 2024 and fell as low as -$1.3 million in Q3 2023.
• Historically, Change in Accured Expenses has averaged $755823.5 across 5 years, with a median of -$49000.0 in 2022.
• Across the five-year window, Change in Accured Expenses sank 1011.32% in 2022 and soared 15655.38% in 2024, its largest moves.
• Year by year, Change in Accured Expenses stood at -$49000.0 in 2022, then sank by 32.65% to -$65000.0 in 2023, then surged by 15655.38% to $10.1 million in 2024, then tumbled by 90.97% to $913000.0 in 2025, then plunged by 107.45% to -$68000.0 in 2026.
• Per Business Quant data, the three most recent Change in Accured Expenses figures were -$68000.0 in Q1 2026, $913000.0 in Q4 2025, and -$210000.0 in Q3 2025.